Search results
Results from the WOW.Com Content Network
Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease. [2] [3] It was being developed by the American pharmaceutical firm Cassava Sciences. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit during its phase III clinical trials. [4]
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
The number of people with dementia is forecast to almost triple by 2050. Around 70% of these cases are likely to be Alzheimer’s disease, the most common form of dementia.
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
Now, research has found that a protein that regulates cell repair could be a promising new target for treating several of these conditions, including the most common, Alzheimer’s disease.
ShutterstockIn 2020, 5.8 million Americans were suffering from Alzheimer’s. According to the CDC, that number is expected to balloon to 14 million by 2060. A cure for those people has long ...
There are three main types of synucleinopathy: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). [1] Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies. [2]
Ahead of two local Alzheimer’s Association events focused on fundraising, education and support for the fight against disease — the Nashville Walk to End Alzheimer's on Nov. 4 and the Dance ...